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Supramolecular Assembly of Aminoethylene-Lipopeptide 
PMO Conjugates into RNA Splice-Switching Nanomicelles
Jasmin Kuhn, Philipp M. Klein, Nader Al Danaf, Joel Z. Nordin, Sören Reinhard, 
Dominik M. Loy, Miriam Höhn, Samir El Andaloussi, Don C. Lamb, Ernst Wagner, 
Yoshitsugu Aoki, Taavi Lehto, and Ulrich Lächelt*
Phosphorodiamidate morpholino oligomers (PMOs) are oligonucleotide 
analogs that can be used for therapeutic modulation of pre-mRNA splicing. 
Similar to other classes of nucleic acid-based therapeutics, PMOs require 
delivery systems for efficient transport to the intracellular target sites. 
Here, artificial peptides based on the oligo(ethylenamino) acid succinyl-
tetraethylenpentamine (Stp), hydrophobic modifications, and an azide 
group are presented, which are used for strain-promoted azide-alkyne 
cycloaddition conjugation with splice-switching PMOs. By systematically 
varying the lead structure and formulation, it is determined that the type of 
contained fatty acid and supramolecular assembly have a critical impact on 
the delivery efficacy. A compound containing linolenic acid with three cis 
double bonds exhibits the highest splice-switching activity and significantly 
increases functional protein expression in pLuc/705 reporter cells in vitro 
and after local administration in vivo. Structural and mechanistic studies 
reveal that the lipopeptide PMO conjugates form nanoparticles, which 
accelerate cellular uptake and that the content of unsaturated fatty acids 
enhances endosomal escape. In an in vitro Duchenne muscular dystrophy 
exon skipping model using H2K-mdx52 dystrophic skeletal myotubes, the 
highly potent PMO conjugates mediate significant splice-switching at very 
low nanomolar concentrations. The presented aminoethylene-lipopeptides 
are thus a promising platform for the generation of PMO-therapeutics with 
a favorable activity/toxicity profile.
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1. Introduction
Antisense oligonucleotides (ASOs) are 
a versatile molecular tool to modulate 
cellular processes by interacting with 
endogenous nucleic acids. Phosphorodi-
amidate morpholino oligomers (PMOs) are 
a class of artificial, uncharged ASOs with 
favorable stability, nuclease-resistance, low 
immunogenicity, and toxi city.[1] A promising 
therapeutic approach based on ASOs is the 
modulation of gene expression by inter-
fering with pre-mRNA splicing.[2] Such 
splice-switching oligonucleotides (SSOs) 
represent innovative therapeutics and could 
be applied for a diverse range of acquired or 
inherited diseases,[3] including neuromus-
cular disorders,[4] thalassemia,[5] inflamma-
tion,[6] retinopathies,[7] and cancer.[8]
Eteplirsen, a PMO for treatment of Duch-
enne muscular dystrophy (DMD) and nusin-
ersen, a phosphorothioate oligonucleotide 
against spinal muscular atrophy (SMA), are 
first examples of approved SSO therapeu-
tics.[9] Similar to other therapeutic nucleic 
acid approaches, SSOs require delivery sys-
tems for efficient transport to their target 
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tissues and intracellular target sites.[10] Previous strategies for 
improved delivery of PMOs have been based on cell-penetrating 
peptides (CPPs),[11] guanidine dendrimers,[12] or cationic backbone 
modifications.[13] Wood and co-workers have developed highly 
potent and well-studied PMO conjugates based on arginine-rich 
CPPs termed Pips that display remarkable efficacy in DMD and 
SMA mouse models.[14]
Although not yet conclusively resolved, for the efficient cel-
lular uptake of guanidinium-containing scaffolds, such as 
arginine-rich CPPs or dendrimers, contribution of nonen-
docyototic translocation mechanisms is discussed.[15] A well-
established alternative chemical motif of intracellular delivery 
systems is based on repeated aminoethylene units, such as 
in polyethylenimine or related polyamines and conjugates.[16] 
Although the exact mechanism also here is still disputed, the 
high efficiency is generally attributed to a characteristic proto-
nation of the repeating aminoethylene units in the endosomal 
range between pH 5 and 7.4 after endocytotic internalization.[17] 
Sequence-defined oligo(ethylenamino) amides based on artifi-
cial oligoamino acids and solid-phase synthesis have been estab-
lished as a delivery platform for charged nucleic acids and other 
therapeutics, which combines the advantages of aminoethylene 
based polymers with the chemical precision and versatility of 
peptides.[18] Here, the synthetic strategy was utilized for the spe-
cific development of new aminoethylene-based PMO conjugates.
2. Results and Discussion
2.1. Conjugate Design and Evaluation
Since PMOs are uncharged nucleic acid analogs, they are 
not prone to the formation of ionic complexes with posi-
tively charged transfecting reagents. Strain-promoted azide-
alkyne cycloaddition, initially established by Bertozzi and 
co-workers,[19] was used for the covalent linkage of diben-
zocyclooctyne (DBCO)-modified PMO and azide-containing 
artificial peptides. For activity screenings and structural optimi-
zations, a PMO sequence against a thalassemic β-globin intron 
mutation IVS2-705 was selected to enable quantitative evalu-
ation of splicing correction in different cell lines containing 
the pLuc/705 construct developed by Ryszard Kole’s lab in the 
1990s. The cells contain a luciferase reporter, which is inter-
rupted by the globin IVS2-705 resulting in increased luciferase 
activity depending on successful splice-switching (Figure S1, 
Supporting Information).[20] Since the construct exhibits a cer-
tain background luciferase activity, luminescence levels were 
always normalized to the background of untreated cells and 
expressed as “fold increase in luminescence.”
2.2. Lead Identification
To assess the general potential of oligo(ethylenamino) amides for 
PMO delivery, a first library screen was conducted with a statistical 
azide-functionalization approach (Figure S2, Supporting Infor-
mation). Selected representatives of cationic polymers (PAMAM 
dendrimer G5, PPI dendrimer G3, LPEI 22 kDa) and artificial pep-
tides with different architectures (branched 3-arm,[21] 4-arm,[17d,22] 
comb-like,[23] PEGylated,[24] and lipid-modified[25]) were first 
functionalized with 1.5 eq. of azidobutyric acid NHS ester, sub-
sequently click-conjugated to PMO-DBCO and finally used for 
transfection of HeLa pLuc/705 cells (Figure S3, Supporting 
Information). Here, the lipopeptide (LP) #991 was identified as 
the most efficient facilitator of PMO-mediated splice-switching. 
It contains the oligo(ethylenamino) acid succinyl-tetraethylene 
pentamine (Stp) as a cationic building unit, cholanic acid as a 
hydrophobic modification and tyrosine, which previously showed 
beneficial effects on charged nucleic acid delivery.[25,26] For further 
validation of this screening hit, a #991 analog with azide-group 
at a defined position, oligomer #1106 (LP CholA),[27] was used 
for transfections in comparison to unmodified #991 and at dif-
ferent PMO to oligomer ratios (Figure 1). Here, 1:1 represents 
the ratio of PMO to LP in the reaction resulting in an equimolar 
mixture of PMO-DBCO + LP CholA (noncovalent, #991) or the 
PMO-LP CholA conjugate (covalent, #1106). Surprisingly, non-
covalent PMO formulations with #991 were also able to mediate 
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Figure 1. PMO-LP conjugation and evaluation. A) The chemical structure 
of the lipopeptide #991 and its analog #1106 with N-terminal azidolysine 
for conjugation to PMO-DBCO via strain-promoted azide-alkyne cycload-
dition (SPAAC). B) The increase in luminescence in HeLa pLuc/705 cells 
24 h after transfection with noncovalent #991 or covalent #1106 formu-
lations at different PMO-DBCO to oligomer ratios. The fold increase in 
luminescence represents arbitrary light units normalized to the mean 
background level of buffer treated cells. Data are presented as mean ± SD 
(n = 3). Additional cell viability data (MTT) are provided in Figure S4 of 
the Supporting Information.
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increased luciferase activity, but only at higher oligomer to PMO 
ratios. Covalent formulations (PMO-LP CholA) were superior in 
all cases, but also here a beneficial effect of additional unconju-
gated LP was evident. To validate the formulation via click reaction, 
HeLa pLuc/705 cells were treated side by side with the PMO-LP 
CholA 1:1 formulation and the purified PMO-LP CholA conjugate 
(Figure S5, Supporting Information). Both PMO formulations 
mediated comparable levels of luciferase activity, which confirms 
the reliability of the formulation approach.
2.3. Structural Variations
First, the impact of the repeated aminoetylene motif in the identi-
fied lipopeptide architecture was assessed in systematic variations 
of the lead structure #1106 by replacement of the contained oli-
goamino acid Stp with basic α-amino acids lysine, arginine, his-
tidine, their combinations, or a 6-aminohexanoic acid-arginine 
motif (RXR).[11c,d] Although the derivatives were designed to con-
tain an equal number of protonatable amines in the biologically 
relevant pH range above pH 5, the substitution of Stp resulted in 
a complete loss of activity (Figure S6, Supporting Information). 
This indicates that the artificial oligoamino acid Stp is an essen-
tial part of this particular lipopeptide architecture, presumably 
due the unique endosomal protonation characteristics of repeated 
aminoethylene motifs. By contrast, substitution of unsaturated 
fatty acids for the cholanic acid part resulted in improved activity 
(Figure S7, Supporting Information). This is in line with previous 
findings that the hydrophobic core of Pip6a derivatives is a critical 
element for efficient PMO delivery.[14a] Based on this observation, 
a series of #1106 analogs containing fatty acids with different 
numbers of unsaturated bonds was synthesized and functional 
luciferase expression was assessed in a kinetic study 12 to 72 h 
after transfection (Figure 2). Here, a distinct dependence of splice-
switching activity on the contained fatty acids and the degree of 
unsaturation was observed: the luminescence increases gradu-
ally with increasing number of unsaturated bonds up to three 
(Figure 2B, left, top). The PMO conjugate containing linolenic acid 
with three double bonds (PMO-LP LenA) promoted the highest 
splice-switching at 5 × 10−6 m concentration. The high activity of 
PMO-LP LenA was not exceeded by conjugates containing fatty 
acids with four to six double bonds (Figure 2B, left, bottom). In 
addition to HeLa, three other cell lines were treated with the same 
set of PMO conjugates to confirm the general ability to mediate 
splice-switching of thalassemic β-globin IVS2-705 (Figure S10, 
Supporting Information). Similar structure–activity relationships 
and significant splice-switching activities were also observed in 
pLuc/705 based human hepatoma (Huh7), murine neuroblastoma 
(Neuro2A), and murine myoblast (C2C12) cells.[28]
The PMO-sequence specificity was assessed in HeLa pLuc/705 
treatments with PMO-LP LenA 1:1 and 1:3 formulations con-
taining either PMO IVS2-705 or 51D (Figure S11, Supporting 
Information). The data illustrate a high increase in lumines-
cence mediated by the specific PMO-705 in contrast to a very low 
unspecific response toward the PMO-51D formulations.
In all transfections the activities of PMO-LP conjugates showed 
a strong dose-dependency. Upon decreasing the concentration 
of PMOs to 0.625 × 10−6 m, the activity and increase in lumines-
cence dropped to low levels (Figure 2B, middle). As observed 
before (Figure 1B), additional unconjugated peptide enhanced the 
splice-switching activity and a high increase in luminescence was 
achieved by the PMO-LP 1:3 formulations at low PMO concentra-
tions (Figure 2B, right, Figure S8, Supporting Information).
A systematic dose titration clearly illustrated the shifted 
splice-switching activities of PMO-LP LenA at 1:1 or 1:3 ratio on 
the RNA and protein activity level (Figure 3). The ratio between 
aberrant and corrected splicing was determined by RT-PCR spe-
cific for a sequence surrounding the β-globin IVS2 (Figure 3A). 
The band intensities of related PCR products (268 bp aberrant, 
142 bp corrected) indicate that complete splicing-correction 
was achieved with PMO-LP LenA 1:3 at a concentration of 
1.25 × 10−6 m PMO whereas, at a 1:1 ratio, 2.5 × 10−6 m PMO 
were required. This also correlates with the dose–response at 
the luciferase activity level (Figure 3B). Bare PMO-DBCO, up 
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Figure 2. Structure–activity and formulation–activity relationships of PMO-LP conjugates. A) A schematic illustration of artificial lipopeptides (LPs) 
with systematic variation of contained fatty acids (FA) with 0 (stearic acid, SteA, C18:0) to 6 (docosahexaenoic acid, DHA, C22:6) all-cis double bonds. 
B) Kinetics of the increase in luminescence between 12 to 72 h after transfection with PMO conjugate formulations at 1:1 (left, middle) or 1:3 (right) 
PMO-DBCO to LP ratio. Fold increase in luminescence represents arbitrary light units normalized to the mean background levels of buffer treated cells. 
Figures show a comparison between LPs containing 0 to 3 (top) or 3 to 6 cis double bonds (bottom). A Pip6a-azide derivative served as a positive 
control in the same PMO-DBCO conjugation protocol at a 1:1 ratio. Data are presented as mean ± SD (n = 3). A complete set of PMO formulations 
at different concentrations are provided in Figures S8 and S9 of the Supporting Information.
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to a concentration of 10 × 10−6 m, was not able to increase lucif-
erase activity significantly. Dose titrations of both PMO-LP LenA 
1:1 and 1:3 formulations side by side revealed equal maximum 
levels between 2.5 and 5 × 10−6 m and an enhanced potency for 
the 1:3 formulation at lower concentrations due to the additional 
fraction of free LP. At the high concentration of 10 × 10−6 m, 
the excess of unconjugated LP (20 × 10−6 m) also mediated 
cytotoxicity (Figure 3C), which was responsible for the drop of 
luciferase activity. An azide-containing derivative of the efficient 
CPP Pip6a served as a positive control and benchmark com-
pound; the PMO-DBCO conjugation was carried out analog 
to the LP formulations at a 1:1 ratio. In direct comparison to 
Pip6a-PMO, PMO-LP LenA 1:3 showed a comparable potency 
at low concentrations, higher maximal luciferase activity, and 
reduced cytotoxicity at higher concentrations. PMO-LP LenA 
1:1 exhibited the best tolerability and no observable signs of 
cytotoxicity or reduced luciferase activity up to a concentration 
of 10 × 10−6 m PMO. Notably, all formulations clearly outper-
formed the commercial noncovalent PMO delivery reagent 
“Endo-Porter,” which was supplemented at constant 6 × 10−6 m 
concentration, as recommended by the distributor.[12,29]
Next, to understand if these structure–activity relationships 
identified under cell culture conditions would also translate to 
a more complex in vivo environment, PMO-LP formulations 
were locally injected into subcutaneous HeLa pLuc/705 xeno-
graft tumors in mice (Figure 4). The quantification of ex vivo 
luciferase activity in the tumor confirmed the two key findings 
of the previous in vitro studies: first, the fraction of free peptide 
in PMO-LP 1:3 formulations enhances splice-switching activity 
(Figure 4A), and second, LP LenA containing linolenic acid 
with three unsaturated bonds is superior to analogs containing 
fatty acids with one (OleA), two (LinA), or four (AraA) double 
bonds (Figure 4B). The studies demonstrate that PMO-LP LenA 
1:3 represents a potent formulation with significant splice 
switching activity in the investigated models.
The exclusive investigation of luminescence levels as final 
result of a complex transfection process is not sufficient to elu-
cidate the underlying mechanisms. Therefore, specific mecha-
nistic studies were conducted to clarify the impact of free LP 
(Figure 5) and unsaturated fatty acids (Figure 6) in the PMO-LPs.
2.4. Particle Formation
To investigate the formation of PMO-LP nanoparticles, fluores-
cence correlation spectroscopy (FCS) experiments with PMO-LP 
LenA 1:1 and 1:3 formulations at various PMO-LP concentra-
tions each containing 50 × 10−9 m Alexa Fluor 647 labeled PMO 
(AF647-PMO) were carried out (Figure 5A). FCS is based on 
the diffusion of fluorescent molecules through a small confocal 
volume (≈1 fL), where the fluorescence signal is recorded and the 
fluctuations analyzed.[30] Changes in the rate of diffusion due to 
the assembly of PMO-LP nanoparticles causes a shift in the tem-
poral autocorrelation function (ACF) of the FCS signal to slower 
timescales. Already at 1.25 × 10−6 m PMO, a significantly slower 
ACF decay of the PMO-LP 1:3 formulation was observed, which 
did not significantly change at higher concentrations. Although, 
a decrease in the decay time of the ACF of the PMO-LP 1:1 for-
mulation was observed at a concentration of 2.5 × 10−6 m, it was 
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Figure 3. Dose–response effects of PMO formulations on HeLa pLuc/705 
cells. A) Detection of corrected β-globin intron splicing by RT-PCR. The 
total RNA was extracted from cells 24 h after PMO-LP LenA 1:1 (top) 
or 1:3 (bottom) treatment and amplified using RT-PCR specific for a 
sequence surrounding β-globin IVS2. Arrows indicate the PCR products 
resulting from unchanged aberrant (268 bp) and corrected (142 bp) 
mRNA splicing. PMO-DBCO was used at 5 × 10−6 m concentration. B) Fold 
increase in luminescence and C) metabolic activity 24 h after treatment 
with PMO-DBCO formulations containing 0.156 to 10 × 10−6 m PMO. 
Free PMO-DBCO, PMO-DBCO formulations with constant 6 × 10−6 m 
“Endo-Porter” reagent (Gene Tools, LLC) and PMO-Pip6a served as refer-
ences. Data are presented as mean ± SD (n = 3).
Figure 4. Ex vivo luciferase activity in subcutaneous HeLa pLuc/705 
tumors 48 h after local injection. A) Comparison of PMO-LP LenA for-
mulations at a 1:1 or 1:3 ratio. B) Comparison of PMO-LP (1:3) formula-
tions with fatty acids containing 1 (OleA), 2 (LinA), 3 (LenA) or 4 (AraA) 
double bonds. A Pip6a-azide derivative served as a positive control in the 
same PMO-DBCO conjugation protocol at a 1:1 ratio. All formulations 
contained 450 µg PMO. Data are presented as mean ± SD (n = 3).
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only at a concentration of 5 × 10−6 m that the decay time of the 
ACF approached that of the 1.25 × 10−6 m of the 1:3 formulation.
These observations indicate a dose-dependent self-associa-
tion and complex formation of PMO-LP formulations. In this 
process, the fraction of free LP in 1:3 formulations seems to 
contribute to the complex assembly at low PMO concentra-
tions. Interestingly, neither labeled PMO-DBCO (at 1 × 10−6 
and 50 × 10−6 m concentrations, Figure S12, Supporting Infor-
mation) nor LP LenA alone (below 10 × 10−6 m concentrations, 
Figures S13 and S14, Supporting Information) showed sub-
stantial supramolecular assembly, compared to the PMO-LP 
LenA formulations. The conjugation seems to change the 
assembly tendency compared to the unconjugated reaction 
partners. Similar findings were obtained by transmission elec-
tron microscopy (TEM, Figure 5B). At a PMO concentration 
of 5 × 10−6 m, spherical nanomicelles were detected in both 
PMO-LP 1:1 and 1:3 formulations, whereas, at 1.25 × 10−6 m 
PMO, similar complexes could only be observed in the 1:3 for-
mulation. Free PMO-DBCO did not form particles at any con-
centration. To address the impact of unconjugated LP on the 
PMO transfection process, cellular uptake of PMO-LP 1:1 and 
1:3 was investigated by confocal laser scanning microscopy 
(CLSM, Figure 5C) and flow cytometry (Figure 5D). Already 
5 min after addition of the formulations to HeLa pLuc/705 
cells, cellular association could be observed in the 1:3 formu-
lation, which rapidly increased over time. Despite the same 
PMO concentration, cellular uptake was significantly enhanced 
15 min after transfection by the fraction of free peptide in the 
1:3 formulation compared to 1:1 (Figure 5D), which presum-
ably is a result of the facilitated complex formation and nano-
particle internalization.[31] The resulting higher PMO uptake 
after 24 h (Figure S21, Supporting Information) is in line with 
the enhanced splice-switching activity mediated by PMO-LP 1:3 
formulations. The intracellular fate of PMO-LP and free LP was 
assessed in an additional CLSM experiment with a PMO-LP 
LenA 1:3 formulation containing AF647-PMO and Alexa Fluor 
488 labeled free LP LenA (Figure 5E). The images verify that 
both separate components co-localize within the cells and seem 
to remain associated up to 24 h after transfection.
2.5. Membrane Interaction
From additional flow cytometry studies, it is evident that the 
beneficial effect of the unconjugated LP in 1:3 formulations 
on the cellular uptake is independent of the different lipid or 
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Figure 5. Impact of free LP in the PMO formulations. A) Fluorescence correlation spectroscopy (FCS) measurements of PMO-LP LenA 1:1 and 1:3 
formulations at different concentrations where 50 × 10−9 m of Alexa Fluor 647 labeled PMO-DBCO (AF647-PMO) was included. The slower decay of the 
autocorrelation function represented by a shift toward higher time lag τ indicates the slower diffusion of AF647-PMO-LP nanoparticles. B) Transmis-
sion electron microscopy (TEM) images of bare PMO-DBCO or formulations with LP LenA at 1:1 and 1:3 ratio. C) Confocal laser scanning microscopy 
(CLSM) images of HeLa pLuc/705 cells 5, 15, or 30 min after transfection with PMO-LP LenA 1:1 or 1:3 (0.625 × 10−6 m PMO) containing 20% AF647-
PMO. D) The uptake of PMO-LP LenA 1:1 and 1:3 (0.625 × 10−6 m PMO) containing 5% AF647-PMO into HeLa pLuc/705 cells 15 min after transfection 
determined by flow cytometry (median fluorescence intensity, MFI, n = 3) is shown. E) CLSM images of HeLa pLuc/705 cells 24 h after transfection with 
PMO-LP LenA 1:3 containing 20% AF647-PMO and 20% Alexa Fluor 488-labeled free LP-LenA (LP-AF488). Nuclei were stained with DAPI (blue), actin 
filaments with rhodamine phalloidin (yellow). The merged channel indicates colocalization (yellow) of AF647-PMO-LP and free LP-AF488. Additional 
FCS, TEM, CLSM, and flow cytometry data are provided in Figures S12–S21 of the Supporting Information.
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fatty acid modifications (Figure S21, Supporting Information). 
1:1 formulations with LP containing cholanic acid or fatty acids 
with 1 to 4 unsaturated bonds mediated comparable levels 
of cellular PMO uptake. In all cases, a distinct PMO uptake 
enhancement was observed in the corresponding 1:3 formu-
lations. Obviously, enhanced cellular uptake can explain the 
advantage of free LP in the formulations, but not the advan-
tage of a specific fatty acid content. Therefore, the high effi-
cacy of LP LenA must be the result of a different mechanism 
associated with the intracellular PMO trafficking. The lipid 
modifications turn the cationic conjugates into amphiphilic 
structures and provide the potential for membrane interac-
tions. It has been shown previously that unsaturated fatty acids 
can mediate pH-dependent membrane lytic activity in nucleic 
acid transfecting agents.[18b,32] For this reason, we hypothesize 
membrane interaction and endosomal release after endocytotic 
internalization as being a potential explanation for the supe-
riority of PMO-LP LenA. An endosomal membrane integrity 
and release assay[17d,33] was carried out with fluorescent calcein 
being loaded into endosomes during transfection with PMO-LP 
SteA (saturated) or PMO-LP LenA (unsaturated) formulations 
(Figure 6A). In both cases, calcein was taken up efficiently 
(Figure 6B) but it was only in the case of PMO-LP LenA that 
a broad and homogenous distribution of fluorescence inten-
sity were evident over the cell indicating release of the fluid 
phase marker calcein from the endosomes. An erythrocyte 
leakage assay verified the pH-dependent membrane interac-
tive potential of PMO-LP containing unsaturated fatty acids 
(Figure 6C). The set of PMO-LP formulations containing CholA 
or fatty acids with zero to four double bonds was incubated 
with erythrocytes at physiological pH 7.4 or endolysosomal pH 
6.5 and 5.5. A clear trend showed an increasing erythrocyte 
leakage, particularly at acidic pH, with an increasing number 
of double bonds. The highest lytic activity was observed with 
PMO-LP LenA and AraA, which altogether supports the initial 
hypothesis of increased endosomal membrane interaction and 
release of the PMO-LP formulation containing unsaturated 
bonds. Additional erythrocyte leakage assays were conducted 
to clarify the contribution of free LP in PMO-LP 1:3 formula-
tions (1 eq. PMO-LP conjugate, 2 eq. free LP) on membrane 
disruption (Figure S22, Supporting Information). Erythrocytes 
were treated with free LP SteA or LenA (2.5, 5, 7.5 × 10−6 m), 
PMO-LP SteA or LenA 1:1 (2.5, 7.5 × 10−6 m) and PMO-LP 
SteA or LenA 1:3 (2.5 × 10−6 m) formulations. The concentra-
tions were chosen to enable direct comparison of equal free 
and total LP contents. Here, several significant observations 
were made. First, the higher lytic activity of LP LenA compared 
to LP SteA was confirmed in all three different states: free 
LP, PMO-LP 1:1 and 1:3 formulations. Second, free LP medi-
ated by far the highest erythrocyte leakage in all cases which 
indicates a reduction of lytic potential due to conjugation. 
Third, PMO-LP 1:3 (2.5 × 10−6 m) exhibited lower lytic activity 
than the corresponding samples with equal amount of free 
(5 × 10−6 m) or total (7.5 × 10−6 m) LP content. Apparently, the 
presence of PMO-LP reduces lytic potential of free LP which 
can be explained by the observed coassembly into nanomicelles. 
Finally, the initially speculated contribution of free LP on mem-
brane disruption was confirmed: in both cases (LP SteA, LP 
LenA), PMO-LP 1:3 formulations mediated higher lytic activity 
than the corresponding 1:1 formulations.
2.6. DMD Myotube Treatment
As an additional model with clinical relevance, an alternative 
PMO sequence 51D[34] mediating exon skipping in H2K-mdx52 
dystrophic skeletal myotubes was selected (Figure 7). In mdx52 
mice, a deletion of dystrophin exon 52 was generated by gene 
targeting,[35] which belongs to the “deletion mutation hotspot”[36] 
of human DMD. H2K-mdx52 myotubes were treated with var-
ying concentrations of PMO-LP LenA 1:1 at (12.5–50) × 10−9 m 
or 1:3  at (2–50) × 10−9 m and Pip6a at 50 × 10−9 m. After 48 h, 
the exon skipping rate of extracted RNA was determined by 
RT-PCR amplification of dystrophin exons 49–54 and micro-
chip electrophoresis. In this in vitro DMD exon skipping 
model the PMO-LP formulations displayed remarkably high 
activity. Both the 1:1 and 1:3 formulations achieved >85% exon 
skipping at a concentration of 50 × 10−9 m. The exon skip-
ping rate mediated by the 1:1 formulation dropped to ≈43% at 
25 × 10−9 m and 24% at 12.5 × 10−9 m concentrations. Con-
sistent with the findings obtained in HeLa pLuc/705 cells, 
also in H2K-mdx52 dystrophic mytobes the PMO conjugates 
strongly benefit from the additional free LP in the formulation. 
PMO-LP LenA 1:3 mediated significantly higher exon skipping 
(≈25% at 2 × 10−9 m, ≈100% at 50 × 10−9 m) compared to PMO-
Pip6a (≈6% at 50 × 10−9 m, ≈77% at 400 × 10−9 m, Figure S23, 
Supporting Information).
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Figure 6. Impact of unsaturated fatty acids on cellular membrane interac-
tions. A) CLSM images of HeLa pLuc/705 cells treated with 0.45 mg mL−1 
calcein and 5 × 10−6 m PMO-LP SteA (1:3) or PMO-LP LenA (1:3) for 4 h. 
B) The cellular calcein fluorescence intensity determined by flow cytom-
etry (median fluorescence intensity, MFI, n = 3) is shown. C) Hemoglobin 
release was determined photometrically for 3.75 × 106 erythrocytes that 
were incubated for 60 min with 2.5 × 10−6 m PMO-LP (1:3) at pH 7.4, 6.5 
and 5.5. Values were normalized to positive control samples treated with 
1% Triton X-100 (100% lysis). Data are presented as mean ± SD (n = 4).
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3. Conclusion
In summary, we report novel aminoethylene lipopeptide-PMO 
conjugates with a high potential for promoting splice-switching 
PMO delivery. During the screening and optimization process, 
two key parameters of highly active formulations were identi-
fied: (1) PMO-LP conjugates containing linolenic acid mediate 
the highest effects, and (2) additional unconjugated LP in the 
formulation enhances the potency and activity at low concen-
trations. The PMO-LP conjugates self-associate into nanocom-
plexes in a concentration-dependent fashion and a fraction of 
additional free LP in the formulation contributes to the par-
ticle formation. The content of unsaturated fatty acid LenA 
was found to facilitate endosomal release after cellular inter-
nalization, most likely via membrane interactions. The splice-
switching activity of the PMO-LP formulations was confirmed 
in human cervix carcinoma (HeLa), human hepatoma (Huh7), 
murine neuroblastoma (Neuro2A), and murine myoblast 
(C2C12) pLuc/705 cells in vitro as well as after local injection 
into HeLa pLuc/705 tumors in vivo. The encouraging splice-
switching activity was additionally confirmed in H2K-mdx52 
dystrophic skeletal muscle cells where the identified PMO-LP 
formulation exhibited remarkably high potency and mediated 
significant exon skipping at low concentration <10 × 10−9 m. 
The presented LP conjugates and formulations are considered 
a highly potent platform for the delivery of PMO therapeutics 
with antisense or splicing-modifying mechanism.
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